Table 3.

State of disease and treatment regiments.

Characteristic			Value
Difference between initial diagnosis of breast cancer and study inclusion (months), median (Q1-Q3)			66.6 (29.4-127.4)
Difference between initial diagnosis of breast cancer metastases and study inclusion (months), median (Q1-Q3)			21.5 (6.8-40.1)
Characteristics of primary tumor (TNM classification), n (%)
	c/y/pTaPTb
		0	7 (3.6)
		1	46 (24.0)
		2	60 (31.3)
		3	15 (7.8)
		4	7 (3.6)
		Other or N/A	57 (29.7)
	c/y/pNcPT
		+	35 (18.2)
		0	23 (12.0)
		1	32 (16.7)
		2	13 (6.8)
		3	6 (3.1)
		Other or N/A	83 (43.2)
	MdPT
		1	57 (29.7)
		0	78 (40.6)
		N/A	57(29.7)
Breast cancer subtype of primary tumor, n (%)
	Hormone receptor positive + HER2e neu negative		101 (52.6)
	HER2 neu positive		63 (32.8)
	Triple negative		14 (7.3)
	N/A		14 (7.3)
Metastases diagnosed at study inclusion, n (%)
	Brain		6 (3.1)
	Lymph nodes		53 (27.6)
	Bone		108 (56.3)
	Lung		55 (28.6)
	Pleura		20 (10.4)
	Liver		66 (34.4)
	Peritoneum		9 (4.7)
	Skin		10 (5.2)
	Other		15 (7.8)
	N/A		4 (2.1)
Previous treatment regiments before study inclusion (Q1-Q3)
	Number of treatment regiments, median		3 (2-4)
	Number of chemotherapeutic treatment lines, median		1 (1-2)
Systemic treatment groups during study period, n (%)
	CDKf 4/6 inhibitors +/– endocrine therapy		41 (21.4)
	Chemotherapy		62 (32.3)
	Endocrine therapy		18 (9.4)
	HER2-targeted therapy		54 (28.1)
	N/A		17 (8.9)

^ac/y/pT: Clinical/after neoadjuvant therapy/pathologic classification of tumor extent and size.

^bPT: Primary tumor.

^cc/y/pN: Clinical/after neoadjuvant therapy/pathologic classification of regional lymph node involvement.

^dM: Metastatic spread.

^eHER2: human epidermal growth factor receptor 2.

^fCDK: cyclin-dependent kinase.